JP2012515213A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515213A5
JP2012515213A5 JP2011546329A JP2011546329A JP2012515213A5 JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5 JP 2011546329 A JP2011546329 A JP 2011546329A JP 2011546329 A JP2011546329 A JP 2011546329A JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5
Authority
JP
Japan
Prior art keywords
cells
individual
combination
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515213A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/021029 external-priority patent/WO2010083298A1/en
Publication of JP2012515213A publication Critical patent/JP2012515213A/ja
Publication of JP2012515213A5 publication Critical patent/JP2012515213A5/ja
Pending legal-status Critical Current

Links

JP2011546329A 2009-01-14 2010-01-14 免疫応答を増強するための、ｍＴＯＲ阻害剤を含有する方法及び組成物 Pending JP2012515213A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14453709P 2009-01-14 2009-01-14
US61/144,537 2009-01-14
US29309610P 2010-01-07 2010-01-07
US61/293,096 2010-01-07
PCT/US2010/021029 WO2010083298A1 (en) 2009-01-14 2010-01-14 Methods and compositions containing mtor inhibitors for enhancing immune responses

Publications (2)

Publication Number Publication Date
JP2012515213A JP2012515213A (ja) 2012-07-05
JP2012515213A5 true JP2012515213A5 (OSRAM) 2012-12-27

Family

ID=42340082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546329A Pending JP2012515213A (ja) 2009-01-14 2010-01-14 免疫応答を増強するための、ｍＴＯＲ阻害剤を含有する方法及び組成物

Country Status (6)

Country Link
US (1) US20100196311A1 (OSRAM)
EP (1) EP2375897A4 (OSRAM)
JP (1) JP2012515213A (OSRAM)
CN (1) CN102281761A (OSRAM)
CA (1) CA2748931A1 (OSRAM)
WO (1) WO2010083298A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906374B2 (en) 2010-04-20 2014-12-09 Cedars-Sinai Medical Center Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
US20150140036A1 (en) * 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
CN105979961B (zh) 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
CN107921050A (zh) * 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
EP3324983A4 (en) 2015-07-20 2019-04-10 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR PRODUCING T-CELLS
US11413309B2 (en) * 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017127729A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
BR112019010470A2 (pt) 2016-11-23 2019-09-10 Novartis Ag métodos de realce de resposta imune com everolimo, dactolisib ou ambos
WO2018106595A1 (en) * 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用
CN114426952A (zh) * 2020-10-29 2022-05-03 中国科学技术大学 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1061949B1 (en) * 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
EP1408106B1 (en) * 2002-10-11 2007-02-14 Sentoclone Therapeutics AB Cancer immuno-therapy
CA2529244C (en) * 2003-06-12 2014-02-18 The Trustees Of The University Of Pennsylvania Rapamycin resistant t cells and therapeutic uses thereof
EP2591775A1 (en) * 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CA2723320C (en) * 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
US8840899B2 (en) * 2008-08-05 2014-09-23 Emory University Use of mTOR inhibitors to enhance T cell immune responses

Similar Documents

Publication Publication Date Title
JP2012515213A5 (OSRAM)
Khosravi et al. Immunologic tumor microenvironment modulators for turning cold tumors hot
Dzutsev et al. Microbes and cancer
Yang et al. Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment
Dallenga et al. Neutrophils in tuberculosisâ   first line of defence or booster of disease and targets for host-directed therapy?
Wang et al. Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy
US9730967B2 (en) Method and system for treating cancer cachexia
JP2015134813A5 (OSRAM)
JP2019512020A5 (OSRAM)
Hu et al. Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice
JP2013541010A5 (OSRAM)
Li et al. Characteristics of CD8+ and CD4+ tissue‐resident memory lymphocytes in the gastrointestinal tract
Lu et al. Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy
Chen et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Wu et al. Matrine ameliorates spontaneously developed colitis in interleukin-10-deficient mice
Xie et al. Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth
Viudez-Pareja et al. Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment
Guo et al. Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis
Yue et al. Harnessing CD8+ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions
Qi et al. P. aeruginosa mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity
Nobel et al. STAT signaling in the intestine
Madan et al. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells
Zhang et al. IL-35 inhibits acute graft-versus-host disease in a mouse model
Huart et al. Could protons and carbon ions be the silver bullets against pancreatic cancer?
Xiong et al. Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor